House Concurrent Resolution No. ___, introduced by Representative Beaullieu, calls on the United States Congress to prioritize and expedite research, clinical trials, and treatment development for Acute Myeloid Leukemia (AML), a rare and aggressive blood cancer with a low five-year survival rate of approximately thirty percent. The resolution highlights the urgent need for improved therapies and early detection methods, particularly in light of the rapid progression of the disease, which can lead to life-threatening complications within days or weeks of diagnosis. The resolution also honors Jonas A. Feeley, who tragically passed away from AML shortly after his diagnosis, emphasizing the personal impact of the disease on families and communities.

The resolution proposes that these federal efforts be collectively recognized as the "Jonas A. Feeley Act," in memory of Feeley and in acknowledgment of all those affected by AML. It urges increased federal investment in biomedical research and innovative treatment options, particularly for vulnerable populations such as veterans who may face higher risks for hematologic malignancies. A copy of the resolution will be sent to key congressional leaders and health organizations to advocate for this important cause.